Blue Light Transurethral Resection and Biopsy of Bladder Cancer with Hexaminolevulinate: Histopathological Characteristics and Recurrence Rates in a Single UK Centre Study

Overview

Journal BJUI Compass

Date 2023 Aug 28

PMID 37636209

Authors

Kimberley Chan

Alexander Hampson

John Hayes

Joshua Rabinowitz

Nikhil Vasdev

Affiliations

Soon will be listed here.

Abstract

Introduction: Blue light cystoscopy with hexaminolevulinate (HAL) during transurethral resection of bladder cancer (TURBT) has been shown to improve detection, thereby reducing bladder cancer recurrence compared with white light cystoscopy.

Methods: Single-centred UK (United Kingdom) study on 101 patients who underwent blue light cystoscopy between July 2017 and November 2020, performed by a single surgeon. Our study was divided into two arms; the primary arm had no prior diagnosis of bladder malignancy ( = 41), whereas secondary re-resection arm had ( = 57). Three patients with non-urothelial bladder cancer were excluded. Patients were followed up for 24 months. Data were collected on biopsy quality, histopathological characteristics and recurrence. The end points of the study were recurrence rate at 24 months in both arms and detection of CIS in patients who undergo TURBT or biopsy after initial white light study in the secondary, re-resection arm. This was analysed with Fisher's exact test.

Results: Of 98 patients, 39 had malignancy in their first blue light TURBT/biopsy: primary arm (10/41, 24.4%) and secondary arm (29/57, 50.9%), with detrusor present in 80.5% and 80.7%, respectively. In the secondary arm, blue light re-resection TURBT detected significantly more CIS (20.7% vs 51.7%, = 0.0277) compared with white light with 3.4% upstaged to muscle invasive bladder cancer (G3pT2). Median time to re-resection was 3.06 months. Recurrence rate was 33.3% in the primary arm and 37.5% in the secondary arm after 24 months of follow-up.

Conclusion: Our data confirm that blue light TURBT with HAL provides superior detection and diagnosis of CIS in patients with previous white light cystoscopy.

Citing Articles

Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study.

Chan K, Hampson A, Hayes J, Rabinowitz J, Vasdev N BJUI Compass. 2023; 4(5):568-574.

PMID: 37636209 PMC: 10447208. DOI: 10.1002/bco2.250.

References

Maisch P, Koziarz A, Vajgrt J, Narayan V, Kim M, Dahm P . Blue versus white light for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021; 12:CD013776. PMC: 8632646. DOI: 10.1002/14651858.CD013776.pub2. View

Chamie K, Litwin M, Bassett J, Daskivich T, Lai J, Hanley J . Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013; 119(17):3219-27. PMC: 3773281. DOI: 10.1002/cncr.28147. View

Herr H . Surgical factors in the treatment of superficial and invasive bladder cancer. Urol Clin North Am. 2005; 32(2):157-64. DOI: 10.1016/j.ucl.2005.02.003. View

Kamat A, Cookson M, Witjes J, Stenzl A, Grossman H . The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis. Bladder Cancer. 2016; 2(2):273-278. PMC: 4927917. DOI: 10.3233/BLC-160048. View

Lotan Y, Chaplin I, Ahmadi H, Meng X, Roberts S, Ladi-Seyedian S . Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. BJU Int. 2020; 127(1):108-113. DOI: 10.1111/bju.15166. View

Witjes J, Bruins H, Cathomas R, Comperat E, Cowan N, Gakis G . European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2020; 79(1):82-104. DOI: 10.1016/j.eururo.2020.03.055. View

Herr H . The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999; 162(1):74-6. DOI: 10.1097/00005392-199907000-00018. View

Veeratterapillay R, Gravestock P, Nambiar A, Gupta A, Aboumarzouk O, Rai B . Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer. Eur Urol Open Sci. 2021; 31:17-27. PMC: 8385287. DOI: 10.1016/j.euros.2021.06.011. View

Heer R, Lewis R, Duncan A, Penegar S, Vadiveloo T, Clark E . Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT. Health Technol Assess. 2022; 26(40):1-144. PMC: 9639219. DOI: 10.3310/PLPU1526. View

10.

Burger M, Grossman H, Droller M, Schmidbauer J, Hermann G, Dragoescu O . Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013; 64(5):846-54. DOI: 10.1016/j.eururo.2013.03.059. View

11.

Lee C, Madii R, Daignault S, Dunn R, Zhang Y, Montie J . Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006; 175(4):1262-7. DOI: 10.1016/S0022-5347(05)00644-0. View

12.

Stenzl A, Roupret M, Witjes J, Gontero P . High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol. 2022; 83(3):193-194. DOI: 10.1016/j.eururo.2022.11.017. View

13.

Sylvester R, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins H . European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021; 79(4):480-488. DOI: 10.1016/j.eururo.2020.12.033. View

14.

Aldousari S, Kassouf W . Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010; 4(1):56-64. PMC: 2812001. DOI: 10.5489/cuaj.777. View

15.

Humphrey P, Moch H, Cubilla A, Ulbright T, Reuter V . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70(1):106-119. DOI: 10.1016/j.eururo.2016.02.028. View

16.

OBrien T, Ray E, Chatterton K, Khan M, Chandra A, Thomas K . Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting.... BJU Int. 2013; 112(8):1096-104. DOI: 10.1111/bju.12355. View

17.

Chan K, Hampson A, Hayes J, Rabinowitz J, Vasdev N . Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study. BJUI Compass. 2023; 4(5):568-574. PMC: 10447208. DOI: 10.1002/bco2.250. View